Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Diabetes is now a pandemic disease. Moreover, a large number of people with prediabetes are at risk for developing frank diabetes worldwide. Both type 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD). Even with statin treatment to lower LDL cholesterol, patients with diabetes have a high residual CVD risk. Factors mediating the residual risk are incompletely characterized. An attractive hypothesis is that remnant lipoprotein particles (RLPs), derived by lipolysis from VLDL and chylomicrons, contribute to this residual risk. RLPs constitute a heterogeneous population of lipoprotein particles, varying markedly in size and composition. Although a universally accepted definition is lacking, for the purpose of this review we define RLPs as postlipolytic partially triglyceride-depleted particles derived from chylomicrons and VLDL that are relatively enriched in cholesteryl esters and apolipoprotein (apo)E. RLPs derived from chylomicrons contain apoB48, while those derived from VLDL contain apoB100. Clarity as to the role of RLPs in CVD risk is hampered by lack of a widely accepted definition and a paucity of adequate methods for their accurate and precise quantification. New specific methods for RLP quantification would greatly improve our understanding of their biology and role in promoting atherosclerosis in diabetes and other disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated plasma TG levels (with the accumulation of TRL and remnant particles) are related not only to subclinical atherosclerosis and vascular inflammation independently of LDL-C in statin-naïve, apparently healthy subjects”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At moderately elevated plasma TG levels, there is increased secretion of large TG-enriched VLDL and chylomicrons from the liver and small intestine that, when combined with suboptimal LpL action in obesity, insulin resistance, and/or diabetes mellitus, results in remnant accumulation.36”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of lipolysis (i.e. complete LPL deficiency) results in the extreme elevation of large ‘nascent’ TRL without any concomitant increase in remnants;36,67,68 here, pancreatitis rather than ASCVD is the major risk.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On a per particle basis, cholesterol-rich remnant particles are more potent inducers of macrophage foam cells than LDL and do not need structural modification to trigger uptake.36,93,141”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“but also equally to residual cardiovascular risk among statin-treated patients, especially those with diabetes mellitus.2,20,36–38”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,983
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 3×
“Furthermore, clinical trials of fibrates and n-3 fatty acids (polyunsaturated fatty acids, also often referred to as fish oils) have, with the exception of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) and JELIS (Japan EPA Lipid Intervention Study), been mostly negative for CVD…”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 1×
“A recent new classification system of T2DM, based on different patient characteristics and risk of diabetes complications, divides adults into five different clusters of diabetes (3).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Abundant epidemiological evidence associated triglyceride levels with CVD risk (11,12), although the risk was often attenuated when adjusted for potential confounders, such as HDL-C (13).”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · cited 1×
“Despite decades of experimental data linking RLPs to atherogenesis in animal models and humans (70), the impact of RLPs as causal mediators in CVD associated with hypertriglyceridemia in patients with T2DM is still uncertain.”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationPathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · cited 1×
“LDL-C concentrations are normal or only slightly elevated, but the LDL particles are characteristically small and dense with triglyceride enrichment (55).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“A key early observation was that a null mutation in APOC3, the gene encoding apoC-III (apoC3), which acts in part by inhibiting LPL, associated with reduced triglyceride levels and reduced CVD risk in an Amish population (15).”
Background
Research works printed but not linked: 1
- Mahley, 1989, Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 1195
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“Very low-density lipoproteins (VLDL), made in the liver, contain apoB100 and are metabolized to VLDL remnants, intermediate-density lipoproteins (IDL), and LDL. Chylomicrons, made in the intestine, are larger and contain apoB48, and are also metabolized to remnant particles but not to IDL and LDL ( Figure 1 ).”
BackgroundInfluentialSelf-citationThe Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Self-citation
Metadata
- Authors
- Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E.
- Affiliations
- University of Washington (US)
- Columbia University (US)
- Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA
- New York University (US)
- Corresponding author
- Bornfeldt, Karin E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 508-516
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085249
- OpenAlex
- W3011963422
- Cited by
- 229
- References
- 72
- Citations by year
- 2026: 26 · 2025: 36 · 2024: 49 · 2023: 46 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL126028, R01HL127694, P01HL092969, R01HL45095, R01HL73029, P01HL128203, R01HL144558, R35HL135833)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047, DP3DK108209)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- remnant lipoproteins, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, residual cardiovascular risk, prediabetes, apolipoprotein E, apolipoprotein B-48, apolipoprotein B-100, chylomicrons, VLDL, lipolysis, atherosclerosis
- MeSH terms
- Animals, Cardiovascular Diseases, Chylomicrons, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, VLDL, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. https://app.cochat.ai/papers/10.2337/dbi19-0007
- The paper
- Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E. (2020). Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. Diabetes. https://doi.org/10.2337/dbi19-0007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.